AzTrials
AzTrials

Major Depressive DisorderPhase 4NCT02141776

Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression

A Phase 4 study testing Transcranial direct current stimulation (t-DCS) in people with Major Depressive Disorder, run by University of Florida at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Major depressive disorder (MDD) is a significant public health problem. Existing treatment modalities are not always sufficient to alleviate this disorder. Treatment refractoriness is a common clinical problem. Read more about this study

Who is it for?
Ages 21 to 65 years
Conditions the study is for
Major Depressive Disorder
What is being tested?
Transcranial direct current stimulation (t-DCS)
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
3 participants
Where
1 siteUnited States
Study dates
May 2014to 8 Jan 2018
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects that meet criteria for Major depressive disorder (MDD)
  • ages 21 to 65 years and
  • who are treatment resistant

Who cannot join

  • Co-morbid substance abuse in last one month.
  • Psychotropic medication changes in last two weeks.
  • Unstable medical or psychiatric problems that need intensive outpatient or inpatient treatment
  • Patients who are not competent to consent for the study
  • Urine pregnancy test positive
  • Ferromagnetic Implanted devices that use electrical or magnetic currents

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Univ of Florida

    Gainesville, Florida, 32606

Other trials in United States

About this study

Official title: A Randomized Blinded Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation of Left Prefrontal Cortex in Patients With Treatment-resistant Depression

Major depressive disorder (MDD) is a significant public health problem. Existing treatment modalities are not always sufficient to alleviate this disorder. Treatment refractoriness is a common clinical problem. Transcranial direct current stimulation (t-DCS), a non-invasive brain stimulation technique, has been shown to be effective in alleviating depressive symptoms in preliminary studies. There is need to explore the role of t-DCS in Treatment-resistant depression (TRD). Therefore, the investigators aim to undertake this exploratory study.

Aim:

Read more

Compare the role of left prefrontal cortex anodal t-DCS daily stimulation of 4 weeks (20 week days) with sham stimulation in alleviating depressive symptoms in patients with TRD.

Methodology: Patients who seek treatment in our treatment resistant depression clinic and who have failed to respond to treatment with two antidepressant medications will be offered to enroll in this study. The aim is to study 20 patients who meet the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for MDD between the ages of 21-65 years. Those subjects that receive sham stimulation will be offered to have active t-DCS stimulation for additional 3 weeks to get any benefit that they may have otherwise missed by being in the sham stimulation group.

Results and Conclusions: The investigators will compare the mean baseline and end of treatment Montgomery Asberg depression rating scale between the two groups. The investigators will compare the change in mean depression scores between the baseline and end of treatment in those receiving active t-DCS for a total of 7 weeks duration. This study is innovative and of significance in exploring the role of this novel, easy to administer, safe and cost effective treatment modality.

Read the detailed description

Research Plan:

  1. Patients who score >10 on our intake screening questionnaire, the patient Health Questionnaire (PHQ-9) will be advised to call to seek participation in this study.
  2. Patients who seek treatment in our treatment resistant depression clinic will be offered to enroll in this study.
  3. Patients who have failed to respond to at least two antidepressants in adequate dosage for at least 4 weeks.
  4. The aim is to have 20 patients complete the study by enrolling 24 patients and screening another 26 patients who meet the diagnostic and statistical manual, DSM-IV criteria for Major depressive disorder, MDD and have failed treatment with at least two antidepressant medications.
  5. Patients will be interviewed by investigators to see if they meet the eligibility for inclusion in the study. The evaluation will consist a medical and psychiatric evaluation if not done in last one year and a monthly urine pregnancy test for women of child bearing potential. If the subjects do not meet the eligibility criteria they will continue to receive routine clinical care or referral for appropriate psychiatric care within or outside of our clinic/department
  6. Stimulation parameters: Left prefrontal anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes. Conductive electrodes covered by sponge soaked in saline will be used. The current will gradually be increased to 2mA over 30 seconds to avoid sensation of a flash.
  7. Patients will be allotted to receive either active or sham stimulation by using a random numbers assignment (www.randomizer.org). Co-investigator Dr. Holbert will be doing the assessments rating the depressive symptoms and he kept blind as to the type of stimulation received. The same machine will be used to give both active and sham stimulation.
  8. At the end of four weeks subjects will be offered to stay in open label extension of this study with active left prefrontal anodal t-DCS for another three weeks to receive any benefits they may otherwise not receive by being in sham stimulation.
  9. Materials: Montgomery Asberg depression rating scale, MADRS, Patient Health Questionnaire, PHQ-9, Clinical Global Impression(CGI) at baseline and weekly. Improvement will be considered as 50 % reduction in depressive scores and remission as a score of less than 9 on MADRS. MADRS is a 10 item examiner rated scale that rates various depressive signs and symptoms and has been used extensively in research of brain stimulation techniques.PHQ-9 is a 9 item self-rated questionnaire about depressive symptoms and has been found reliable in studies of depression in primary care and psychiatric settings. CGI is a clinician rated impression about treatment response.

Procedure outline:

Baseline: diagnostic interview, evaluation of inclusion and exclusion criteria, urine pregnancy test if indicated at baseline and day 31, filling in questionnaires: PHQ-9, MADRS, CGI Daily: t-DCS stimulation for 30 minutes; patients will be asked about any discomfort/side effects.

Days: 7,14,21,28,35,42,49: PHQ-9, MADRS, CGI

Specifically, the investigators will compare baseline to post treatment depression scores via a two-sample t-test, comparing active treatment to sham using a two-sided P-value <0.05 to declare significance. The change in MADRS score (MADRS) will be the primary outcome variables. Secondary variables will be analyzed similarly in this pilot study. Significant findings on secondary variables will not be considered as definitive.

Being tested
Transcranial direct current stimulation (t-DCS), Sham Controlled Arm
Medical subject headings
Depressive Disorder, Major

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcranial direct current stimulation (t-DCS)Device

    The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.

  • Sham Controlled ArmOther

    The subjects randomized to this group will not receive stimulation daily for four weeks.

Study groups in NCT02141776
Study groupRoleWhat they receive
Sham Controlled ArmSham comparatorThe subjects randomized to this group will not receive stimulation daily for four weeks.
Receives: Other: Sham Controlled Arm
Transcranial direct current stimulation (t-DCS)Active comparatorThe subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
Receives: Device: Transcranial direct current stimulation (t-DCS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Montgomery Asberg depression rating scale score

    Investigators will measure the changes in Montgomery Asberg depression rating scale scores with trans-cranial direct current stimulation

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2014 (estimated)
  2. Study startMay 2014
  3. Primary completion8 Jan 2018
  4. Study completion8 Jan 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
3 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02141776
Sponsor's protocol ID
95-2013
Other IDs
IRB201501014
Status last verified
Jan 2018
First submitted
15 May 2014
Last updated
12 Jan 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Transcranial direct current stimulation (t-DCS) in people with Major Depressive Disorder, run by University of Florida at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Montgomery Asberg depression rating scale score (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in